Fueling the failing heart: SGLT2i directly activates the hidden PANK1.

SGLT2 inhibitors bind directly to cardiac pantothenate kinase 1 (PANK1), boosting coenzyme A biosynthesis to support energy metabolism and functional recovery in the heart.

• Why it matters: Heart failure therapies are improving, but the direct molecular mechanism behind SGLT2 inhibitor benefits has been unclear.
• What they did: Forelli and colleagues report that SGLT2 inhibitors directly interact with cardiac PANK1 and measure downstream effects on coenzyme A biosynthesis and energy metabolism.
• The result: The findings link SGLT2 inhibitor action to PANK1-driven coenzyme A production, providing a mechanistic basis for energy support and functional recovery in cardiac settings.

AI summary of the abstract · may contain errors · not medical advice · read the paper.